NASDAQ:INSM Insmed (INSM) Stock Price, News & Analysis $106.24 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$106.50 +0.26 (+0.24%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Insmed Stock (NASDAQ:INSM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Insmed alerts:Sign Up Key Stats Today's Range$106.20▼$110.8350-Day Range$101.17▼$164.8652-Week Range$65.56▼$212.75Volume2.43 million shsAverage Volume4.03 million shsMarket Capitalization$23.03 billionP/E RatioN/ADividend YieldN/APrice Target$210.95Consensus RatingModerate Buy Company Overview Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options. The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S. Food and Drug Administration for use in adults with refractory Mycobacterium avium complex (MAC) lung disease. ARIKAYCE is designed to deliver high concentrations of antibiotic directly to the lungs, and Insmed has pursued both commercial uptake and further regulatory and clinical work to explore additional indications and geographic approvals. Beyond its marketed product, Insmed maintains a clinical-stage pipeline focused on pulmonary and other rare disease indications, leveraging formulation science and targeted delivery approaches. The company conducts clinical trials, regulatory interactions, and commercial activities aimed at expanding patient access to its therapies. Insmed also engages in partnerships and business development efforts to support international registrations and distribution. Insmed presents itself as a specialty biopharma organization combining R&D, regulatory, and commercial capabilities to serve patients with high unmet medical need. Its operations encompass clinical development, regulatory strategy, manufacturing partnerships for specialized formulations, and patient support programs intended to facilitate access and adherence for those living with chronic and complex conditions.AI Generated. May Contain Errors. Read More Insmed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreINSM MarketRank™: Insmed scored higher than 70% of companies evaluated by MarketBeat, and ranked 236th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingInsmed has received a consensus rating of Moderate Buy. The company's average rating score is 2.96, and is based on 1 strong buy rating, 23 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialInsmed has a consensus price target of $210.95, representing about 98.6% upside from its current price of $106.24.Amount of Analyst CoverageInsmed has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insmed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Insmed are expected to grow in the coming year, from ($2.52) to $0.86 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insmed is -18.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Insmed is -18.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInsmed has a P/B Ratio of 32.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Insmed's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.93% of the float of Insmed has been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Insmed has recently increased by 6.16%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInsmed does not currently pay a dividend.Dividend GrowthInsmed does not have a long track record of dividend growth. News and Social Media4.4 / 5News Sentiment1.08 News SentimentInsmed has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Insmed this week, compared to 12 articles on an average week.Search Interest36 people have searched for INSM on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows7 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Insmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,513,766.00 in company stock.Percentage Held by Insiders2.10% of the stock of Insmed is held by insiders.Percentage Held by InstitutionsInsmed has minimal institutional ownership at this time.Read more about Insmed's insider trading history. Receive INSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INSM Stock News HeadlinesSA Asks: What are the most attractive biotech stocks right now?May 25 at 9:12 AM | seekingalpha.comMichael Alexander Smith Sells 6,149 Shares of Insmed (NASDAQ:INSM) StockMay 23 at 8:23 AM | insidertrades.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.May 25 at 1:00 AM | Behind the Markets (Ad)Insmed, Inc. (NASDAQ:INSM) Receives Average Rating of "Moderate Buy" from BrokeragesMay 22 at 2:48 AM | americanbankingnews.comInsmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 20, 2026 | seekingalpha.comCompetitive Pressures Prompt Truist to Cut Target on Insmed (INSM)May 20, 2026 | finance.yahoo.comAssessing Insmed (INSM) Valuation After Recent Share Price Pullback And Strong Multi Year ReturnsMay 19, 2026 | finance.yahoo.comInsmed Shareholders Approve Directors, Executive Pay at 2026 Annual MeetingMay 18, 2026 | americanbankingnews.comSee More Headlines INSM Stock Analysis - Frequently Asked Questions How have INSM shares performed this year? Insmed's stock was trading at $174.04 at the start of the year. Since then, INSM shares have decreased by 39.0% and is now trading at $106.24. How were Insmed's earnings last quarter? Insmed, Inc. (NASDAQ:INSM) announced its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.14. Insmed's revenue for the quarter was up 229.7% on a year-over-year basis. Read the conference call transcript. Who are Insmed's major shareholders? Top institutional shareholders of Insmed include Bank of America Corp DE (0.69%), Sei Investments Co. (0.64%), Bank of New York Mellon Corp (0.59%) and Pictet Asset Management Holding SA (0.51%). Insiders that own company stock include William Lewis, Melvin Md Sharoky, John Drayton Wise, Roger Adsett, David W J Mcgirr, Martina MD Flammer, Sara Bonstein, Elizabeth M Anderson, Leo Lee, Orlov S Nicole Schaeffer, Michael Alexander Smith, Clarissa Desjardins and Clarissa Desjardins. View institutional ownership trends. How do I buy shares of Insmed? Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Insmed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Insmed investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings5/07/2026Today5/25/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 INSM's financial health is in the Red zone, according to TradeSmith. INSM has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INSM CIK1104506 Webwww.insmed.com Phone908-977-9900Fax732-438-0381Employees1,664Year FoundedN/APrice Target and Rating Average Price Target for Insmed$210.95 High Price Target$263.00 Low Price Target$135.00 Potential Upside/Downside+98.6%Consensus RatingModerate Buy Rating Score (0-4)2.96 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)($5.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.28 billion Net Margins-144.44% Pretax Margin-143.76% Return on Equity-130.11% Return on Assets-51.57% Debt Debt-to-Equity Ratio0.80 Current Ratio4.47 Quick Ratio4.10 Sales & Book Value Annual Sales$819.56 million Price / Sales28.10 Cash FlowN/A Price / Cash FlowN/A Book Value$3.25 per share Price / Book32.69Miscellaneous Outstanding Shares216,752,000Free Float212,200,000Market Cap$23.03 billion OptionableOptionable Beta0.89 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:INSM) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
